Can We Simplify the Treatment of Myelofibrosis?
In this randomized trial, momelotinib was non-inferior to ruxolitinib for spleen response but was less effective in controlling symptoms. Related Article: SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor\u2013Na\xefve Patients With Myelofibrosis